146 related articles for article (PubMed ID: 27424184)
1. Chemoradiation of locally advanced squamous cell carcinoma of the head-and-neck (LASCCHN): Is 20mg/m(2) cisplatin on five days every four weeks an alternative to 100mg/m(2) cisplatin every three weeks?
Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Karner K; Strojan P; Schild SE
Oral Oncol; 2016 Aug; 59():67-72. PubMed ID: 27424184
[TBL] [Abstract][Full Text] [Related]
2. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: Higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks.
Rades D; Strojan P; Seidl D; Janssen S; Bajrovic A; Kazic N; Hakim SG; Wollenberg B; Schild SE
J Craniomaxillofac Surg; 2016 Sep; 44(9):1436-40. PubMed ID: 27499514
[TBL] [Abstract][Full Text] [Related]
3. Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers.
Rades D; Seidl D; Janssen S; Bajrovic A; Karner K; Strojan P; Schild SE
BMC Cancer; 2016 Jul; 16():437. PubMed ID: 27391309
[TBL] [Abstract][Full Text] [Related]
4. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head-and-neck cancer?
Rades D; Seidl D; Janssen S; Bajrovic A; Hakim SG; Wollenberg B; Schild SE
Oral Oncol; 2016 Jun; 57():40-5. PubMed ID: 27208843
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Factors After Definitive Radio(Chemo)Therapy of Locally Advanced Head and Neck Cancer.
Seidl D; Janssen S; Strojan P; Bajrovic A; Schild SE; Rades D
Anticancer Res; 2016 May; 36(5):2523-6. PubMed ID: 27127167
[TBL] [Abstract][Full Text] [Related]
6. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
[TBL] [Abstract][Full Text] [Related]
7. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment subcutaneous adipose tissue predicts the outcomes of patients with head and neck cancer receiving definitive radiation and chemoradiation in Taiwan.
Pai PC; Chuang CC; Chuang WC; Tsang NM; Tseng CK; Chen KH; Yen TC; Lin CY; Chang KP; Lei KF
Cancer Med; 2018 May; 7(5):1630-1641. PubMed ID: 29608254
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
10. Weekly versus every-three-weeks platinum-based chemoradiation regimens for head and neck cancer.
Melotek JM; Cooper BT; Koshy M; Silverman JS; Spiotto MT
J Otolaryngol Head Neck Surg; 2016 Nov; 45(1):62. PubMed ID: 27881143
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y
Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
13. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
[TBL] [Abstract][Full Text] [Related]
14. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
16. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of p65 (RelA) in patients receiving post-operative radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Rades D; Huttenlocher S; Seibold ND; Gebhard MP; Thorns C; Hasselbacher K; Wollenberg B; Schild SE
BMC Cancer; 2015 Mar; 15():102. PubMed ID: 25868613
[TBL] [Abstract][Full Text] [Related]
18. The impact of cumulative dose of cisplatin on outcome of patients with head and neck squamous cell carcinoma.
Al-Mamgani A; de Ridder M; Navran A; Klop WM; de Boer JP; Tesselaar ME
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3757-3765. PubMed ID: 28755023
[TBL] [Abstract][Full Text] [Related]
19. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck.
Seibold ND; Schild SE; Bruchhage KL; Gebhard MP; Noack F; Rades D
Strahlenther Onkol; 2013 Aug; 189(8):639-46. PubMed ID: 23748230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
